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INTRODUCTION 
 The development of newborn screening is one of the most significant advancements in 
public health genetics. It is the practice of testing all babies for certain disorders, diseases and 
conditions that may hinder their normal development.  In the United States alone, more than four 
million newborns are screened shortly after birth for certain genetic diseases, in addition for 
screening for non-genetic conditions.
1
  While early detection and treatment can help prevent 
physical and intellectual disabilities, as well as life threatening illnesses, the early detection of 
some disorders that are required to be tested, cannot be cured, but rather, through therapies and 
intervention may be treatable or preventable. 
 This concept of ‘treatability’ is interesting considering that several diseases not required 
to be screened as recommended by the Department of Health and Senior Services (DHS) and 
state law, through intervention and therapies, are treatable.  This perhaps should reveal the most 
obvious aspect of newborn screening in the United States- that the diseases, disorders and 
conditions screened vary from state to state.   
 The Supreme Court’s recent decision to uphold the Patient Protection and Affordable 
Care Act (ACA) supports the importance of recommending the nation-wide insurance coverage 
of diseases and disorders that are required to be tested through newborn screening.  It also brings 
us closer to the institution of these federally recommended diseases in state newborn screening 
panels. Importantly, the law also stipulates that insurance companies must pay for the newborn 
screening of diseases recommended by DHS.  This is a great achievement in the effort to assure 
                                                        
1
 See NIH Program Explores the Use of Genomic Sequencing in Newborn Healthcare, 
http://www.nih.gov/news/health/sep2013/nhgri-04.htm, (last visited Dec. 8, 2013). 
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that all newborn babies are tested for these diseases and disorders that may save or improve the 
quality of their young lives.
2
. 
 Despite this laudable achievement in the law, it is important to note that not all of the 
disorders, conditions and diseases generally required to be tested under the federal panel can be 
cured.  Rather, many of these conditions, can be treated or their onset delayed through the early 
detection of the presence of the gene.   This presents several ethical considerations and questions 
as to why certain diseases in this non-treatable category are not tested through the newborn 
screening process.   
In recent years, in particular, there has been a public push to add neurological diseases to 
newborn screening panels across the country.  Such diseases include Alzheimer’s disease and 
Krabbe disease, also referred to as globoid cell leukodystrophy.  Alzheimer’s disease is an 
irrevererable, progressive brain disease that slowly deteriorates memory and thinking abilities.
3
  
At its most debilitating stages, individuals with Alzheimer’s disease must rely on others to 
complete the simplest of tasks.
4
  Krabbe disease is an untreatable neurological disorder that leads 
to extreme muscle weakness and slowed mental and physical development.
5
  It eventually leads 
to death.
6
 New Jersey and New York are among the few states to test for Krabbe’s disease.  
 This paper will the will present a comparative analysis as to the diseases tested under 
newborn screening under the ACA, New Jersey and New York state law.  It will discuss the 
significance of the ACA to newborn screening in the United States.  This paper will also focus 
on the inclusion of Krabbe’s disease to New York and New Jersey’s Newborn screening panels 
                                                        
2
See Health Care Reform Law Benefits Children with Genetic Diseases: Despite the law’s benefits, many questions 
about coverage remain, http://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.35676/full, (Last visited Dec. 8, 2013).  
3
 See National Institute off Aging, Alzheimer’s disease Fact; Sheet 
http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet (Last visited Dec. 8, 2013). 
4
 See id.  
5
 See Krabbe Disease, http://ghr.nlm.nih.gov/condition/krabbe-disease, (Last visited Dec. 8, 2013). 
6
 See id.  
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and why its inclusion represents a milestone so that other neurological disorders, such as Early-
onset Alzheimer’s disease can be included.  It will conclude with why Early-Onset Alzheimer’s 
should be added to the federally recommended Uniform Screening Panel. 
Part I of this paper will focus on the process and history of newborn screening in the 
United States.  Part II of this paper will explore the changes made to newborn screening under 
the ACA and what is required of insurance companies under the Act.  It will also break down the 
diseases approved by the Secretary of DHS to be included in the Recommended Newborn 
Screening Panel (RNSP) and what diseases are curable, treatable through intervention, and not 
treatable.  Part III will explore the diseases required to be screened under New Jersey and New 
York’s newborn screening laws. Part IV will explore what Early Alzheimer’s disease is and will 
argue that it should be added to the list of diseases screened at the federal level.  It will also 
discuss therapies and interventions that can reduce the risk of the disease and urge that the 
availability of these interventions supports its inclusion on the federal RNSP.  This writing will 
conclude with Part V which will close with why Early-Onset Alzheimer’s disease should be add 
to newborn screening panels, both in New York and New Jersey in addition to the federally 
recommended list of diseases screened for.  
 
IV. THE PROCESS AND HISTORY OF NEWBORN SCREENING 
 
Newborn screening is a medical test that is performed on infants shortly after birth that 
occurs by taking a sample of an infant’s blood and analyzing it for abnormal genes types, 
 5 
enzymes, metabolites and other chemicals.
7
 This test was established to diagnosis and detect the 
presence of life-threatening disorders in infants.
8
  The newborn screening procedure is a non-
invasive blood test in which a small sample of blood is collected by simply taking a sample of 
blood from an infant’s heal.9  It is then analyzed for abnormal gene types, enzymes, metabolic 
and other chemicals that may lead to the diagnosis of a disorder.
10
  This is usually performed in a 
laboratory and the results are provided to medical professionals usually within twenty-four (24) 
hours.
11
 
Dr. Robert Guthrie developed the newborn screening test in the 1960s.  Dr. Guthrie 
initially began his career as a principal cancer scientist that the Roswell Park Cancer Institute in 
Buffalo, New York.
12
  After the birth of his second son John, who was born with 
phenylketonuria (PKU), he then altered his career and dedicated his research to altering and 
measuring phenylalanine levels in the blood of infants who acquired PKU in order to find a cure 
and treat his son.
13
 Through his research, he developed the newborn screening test, a relatively 
easy procedure. Basically, within the first twenty-four hours of life, three to four droplets of an 
infant’s blood are collected and placed on special filter paper.14  The sample is then dried and 
sent out to a special laboratory for testing.  The results are received usually within a day. The 
most important result was that through the Guthrie method of newborn screening, a definitive 
therapy for treating PKU was able to be administered to infants before the neurotoxicity that 
                                                        
7
 See Association of Public Health Laboratories, What is newborn Screening, 
http://www.aphl.org/aphlprograms/newborn-screening-and-genetics/50th-Anniversary-of-Newborn-
Screening/Pages/What-is-Newborn-Screening.aspx, (Last visited Dec. 8, 2013). 
8
 See id. 
9
 See id. 
10
 See id. 
11
 See id. 
12
  See Jason Gonzalez & Monte S. Willis, Robert Guthriem MD, PhD, Clinical Chemistry/Microbiology, 
LABMEDICINE, 40, 748-749 (2009).  
13
 See id. 
14
 See id. 
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resulted from PKU became fatal.
15
 Thus, it helped to save the lives of the infants affected by this 
debilitating disease. 
In the United States, newborn screening began with the testing for genetic disease PKU.  
PKU is a genetic disorder the results in an individual’s inability to produce the specific enzyme 
that causes a buildup of the amino acid phenylalanine.
16
  An accumulation of the amino acid 
phenylalanine produces several physical and mental symptoms such as stunted growth, seizures, 
hyperactivity, sudden uncontrolled movements of the arms and legs, skin rashes and mental 
retardation.
17
  In addition, phenylalanine affects the body’s production of melanin, the pigment 
that determines the hair and skin color of an individual.
18
  Therefore, infants with this condition 
often have lighter skin, hair and eyes than their brothers and sisters.
19
 Fortunately, if PKU is 
diagnosed within the first few days of life, it is treatable and the majority of its symptoms can be 
avoided or reversed.
20
   This is accomplished by constricting the amount of phenylalanine 
consumed in the infant’s daily diet.21  It also requires that a doctor or registered dietician closely 
monitor the individuals diet.
22
  Infants, who are treated for PKU within the first few weeks of 
life, are able to lead normal, healthy lives.
23
 
The original purpose of newborn screening had two main goals.
24
  First, the programs 
were created to the monitor the health of the infant population in the United States.
25
  Second, 
                                                        
15
 See id. 
16
 See id. 
17
  See id. 
18
 See A.D.A.M. Medical Encyclopedia, Phenylketonuria, 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002150/, (Last visited Dec. 6, 2013) 
19
 See id. 
20 See id. 
21 See id. 
22 See id. 
23 See id. 
24
 See Rachel L. Schweers, Ph.D, Newborn Screening Programs: How Do We Best Protect Privacy Rights While 
Ensuring Optimal Newborn Health?, 61 DEPAUL L. REV. 869, 875 (2012). 
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the programs were intended to detect metabolic abnormalities in infants that were known, at the 
time, to have severe consequences such as death, that were easily discoverable through a simple 
blood test.
26
   
With this scientific advancement, and in response to advocacy of geneticists, the medical 
community and parents, states began establishing newborn screening programs.   The first state 
to mandate a newborn screening programswas Massachusetts.
27
   They started testing for PKU 
and added other diseases as they were discovered.
28
 By the early 1970’s all fifty states created 
programs with the support of the medical community. 
29
  They followed the Massachusetts lead, 
which resulted in approximately ninety percent of all newborns in the United States being tested 
for PKU.
30
  
For the next ten years, states continued to add disorders to their newborn screening 
program.   One important aspect of these new additions to newborn screening programs was that 
only disorders were included if treatment could avert serious harm to the affected child.
31
  From 
then on, newborn screening has become a permanent part of infant health care in the United 
States.  Today, all states, including the District of Columbia have implemented successful 
newborn screening programs to test for numerous metabolic and genetic disorders.
32
  Although, 
it is important to note that not all of the diseases recommended by the RNSP are tested for in 
each state. 
 
                                                                                                                                                                                  
25
 See id. 
26
 See id. 
27
 See id. Diane B. Paul, The History of Newborn Phenylketonuria Screening in the U.S., in Final Report of the Task 
Force on Genetic Testing, Appendix 5 (Neil A. Holtzman & Michael S. Watson eds., 1997). 
28
 See id. 
29
 See Ellen Wright Clayton, State Run Newborn Screening In The Genomic Era, Or How To Avoid Drowning When 
Drinking From A Fire Hose, 38 J.L. MED. & ETHICS 697 (2010). 
30
  See id. 
31
 See id. 
32
 See id. 
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A. The Expansion of Diseases Tested in Newborn Screening Programs 
 
As a result of the ever-increasing advancements in science through technology and 
genetics, states have continued to expand the disorders, diseases and conditions tested for in their 
newborn screening programs.   Many of these diseases included not only diseases that benefit 
from intervention at infancy, such as PKU, but also for diseases for which there is no known 
treatment, cure or intervention available. Such diseases include Huntington’s disease and some 
forms of Krabbe Disease.
33
  In addition, diseases for which a prediction of diagnosis is given 
based upon an individual’s genetics are also included.34 
The accuracy and validity of predicting a diagnosis of a certain disease or disorder is, to 
date, one of the most controversial aspects of newborn screening programs.  In fact, some 
medical professional organizations do not fully support predictive testing to reveal the propensity 
of diseases with no exiting treatment or for which the disease does not physically present itself 
until post-childhood.
35
  However, despite this controversy, in recent years there has been a 
significant drive from advocacy, interest groups, and lobbyists to add diseases such as Krabbe's 
disease, also known as Globoid Cell Leukodystroph, to the list of conditions screened.
36
  This is 
significant because the onset of Krabbe disease varies.
37
 
In 1968, Maxwell Grove Wilson, the then Principal Medical Officer at the Ministry of 
Health in London, England, and Gunner Jungner, the then Chief of the Clinical Chemistry 
                                                        
33
 See About Newborn Screening, Conditions Screened by State, http://www.babysfirsttest.org/newborn-
screening/states, (last visited Dec. 8, 2013). 
34
 See Beth A. Tarini et al., Not Without My Permission: Parents' Willingness to Permit Use of Newborn Screening 
Samples for Research, 13 PUB. HEALTH GENOMICS 125,127 (2010).  
35
 See Beth A. Tarini et al., Parents' Interest in Predictive Genetic Testing for Their Children when a Disease Has 
No Treatment, 124 PEDIATRICS 432, 435 (2010). 
36
 See Krabbe Newborn Screening, Information for Parents whose Baby Screened Positive for Krabbe Disease, 
http://www.huntershope.org/site/PageServer?pagename=unbs_krabbe_newborn_screening, (Last visited Dec. 7, 
2013). 
37 Please refer to Part 3, section A of this paper for a more detailed explaination on the onset of Krabbe disease. 
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Department of Sahlgren’s Hospital in Gothenburg, Sweden, published a report that established a 
set of classic criteria, which still remain influential in defining what disorders and diseases 
should be deemed suitable for inclusion in newborn screening and genetic screening both on the 
state and federal level.
38
 The report was entitled, Principles and Practice of Screening for 
Disease.
39
  
Despite being established many years ago, these core principles remain relevant today.
40
   
The principles are generally as follows.  First, the disease must be well defined and serious.
41
  
Second, there must be an accurate testing method available.
42
  Third, the costs of the test must be 
reasonable.  Fourth, there must be available treatment for the disorder.
43
  And last, there must be 
adequate medical management facilities to refer infants for confirmatory diagnosis and 
treatment.
44
 
 With this framework in mind, the next part of this paper will explore the significance of 
the ACA followed by an analysis of newborn screening laws in New Jersey and New York. 
 
V. NEWBORN SCREENING IN THE PATIENT PROTECTION AND AFFORDABLE CARE ACT 
 
The single most significant development in healthcare law was the Supreme Court’s 
decision to uphold the Patient Protection and Affordable Care Act (ACA).    In the landmark case 
                                                        
38
 See  Anne Andermann, Ingeborg Blancquaert, Sylvie Beauchamp & Véronique Déry, Revisiting Wilson And 
Jungner In The Genomic Age: A Review Of Screening Criteria Over The Past 40 Years, BULLWORLD HEALTH ORG, 
2008 Apr;86(4):317-9. 
39
 See id. 
40
 See id. 
41
 See  Maxwell Grove Wilson & Gunner Jungner, Principles and Practice of Screening for Disease, 27-8,WORLD 
HEALTH, PUBLIC HEALTH PAPERS NO. 34 (1968). 
42
 See id. 
43
 See id. 
44
 See Eileen M. McKenna, The Mandatory Testing of Newborns for HIV: Too Much, Too Little, Too Late, 13 
N.Y.L. SCH. HUM. RTS. 307, 327-28 (1997).   
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National Federal of Independent Business v. Sibelius, several states filed suit against Secretary 
Sibelius based upon the constitutionality of the Patient Protection and Affordable Care Act 
signed into law by President Barak Obama on March 23, 2010.  
The Court found that the Medicaid expansion mandate under the Affordable Care Act was 
unconstitutional, because states did not have adequate notice to voluntarily consent to the new 
Medicaid expansion provision.  In addition, the Court held that if a state did not comply with the 
new law, the Secretary could withhold all of a state’s existing federal Medicaid funds.45   Despite 
this, the majority of the Supreme Court still found that this issue was appropriately remedied 
through the ACA.  Thus, the ACA expansion was upheld.  
As a result of this ruling by the Supreme Court, all provisions and mandates in the ACA 
remain effective.  This signifies an important landmark for newborn screening.  According to the 
ACA, insurance companies are now required to provide coverage for newborn screening of 
diseases that are federally recommended
46
.   
 Section 2713, Coverage for Preventable Health Services of the ACA states: 
(a) IN GENERAL- a group health place and a health insurance insurer offering group or 
individual health insurance coverage shall, at a minimum provide coverage for and 
shall not impose any cost sharing requirements for- 
(3) With respect to infants, children, adolescents, evidence-informed 
preventative care and screenings provided for in the comprehensive guidelines 
supported by the Health Resources and Services Administration.
47
 
 
This provides that all the conditions added to the panel of diseases recommended to be screened 
by the Secretary’s Discretionary Advisory Committee on Heritable Diseases in Newborns and 
Children must be covered by insurance, regardless of whether or not a state requires screening 
for that specific newborn disease. This is significant because not all states test for the diseases 
                                                        
45
 See id. 
46
 The Patient Protection and Affordable Care Act, 42 U.S.C. § 2713 (2010). 
47
 See id. 
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recommended by the federal government.  Therefore, mandating that insurance pay for all the 
diseases recommended by the federal government provides newborns with more thorough 
screening exams and can save more infant lives. 
The Discretionary Advisory Committee on Heritable Disorders in Newborns and 
Children was established under the Public Health Service Act (PHS), 42 U.S.C. 217, Advisory 
Councils or Committees.
48
  The Committee on Heritable Diseases in Newborns and Children 
recommends that every newborn screening panel in the country screen for the thirty-one core 
disorders and twenty-six secondary disorders recommended by the Uniform Screening Panel.
49
   
The Uniform Screening Panel defines primary disorders as those disorders for which medical 
evidence suggests that there is a medical benefit for detecting the disorder in infants.
 50
  The 
Panel defines secondary disorders as those disorders that can be detected while screening for the 
primary disorders.
51
 These disorders include metabolic disorders
52
, Endocrine Disorders
53
, 
Hemoglobin Disorders
54
 and other disorders such as Biotinidase deficiency, Critical Congenital 
Heart Disease, Cystic Fibrosis, Classic Galactosemia, Hearing loss and severe combined 
                                                        
48
See Discretionary Advisory Committee on Heritable Disorders In Newborns and Children, 
http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/, (Last visited Dec. 6, 2013). 
49
 See id. 
50
 See Virginia A. Moyer, Ned Calonge, Steven M. Teutsch, and Jeffrey R. Botkin, on behalf of the United States 
Preventive Services Task Force, Expanding Newborn Screening: Process, Policy, and Priorities, HASTINGS CENTER 
REPORT 38, no. 3, 32-39 (2008). 
51 See id. 
52
 See  Recommended Uniform Screening Panel Core Conditions, 
http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendedpanel/uniformscreeningpa
nel.pdf (as of April 2013). Metabolic Disorders occur when abnormal chemical reactions in your body disrupt the 
process your body to make energy from the food you consume.  They include Organic Acid Conditions, Fatty Acid 
Oxidtion Disorders and Amino Acid Disorders. 
53
 See id.  Endocrine disorders occur when your hormone levels are too high or too low. Hormone diseases also 
occur if your body does not respond to hormones the way it is supposed to. 
 
54
 See id. Hemoglobin disorders is produced by genes that control the expression of the hemoglobin protein. Defects 
in these genes can produce abnormal hemoglobins and anemia 
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immunodeficiencies
55.  Currently, no state’s newborn screening panel requires all thirty-one 
primary disorders to be screened.  However, several states screen for all but one or two disorders.  
According to the Genetic Alliance, insurance companies have one year from when a condition is 
recommended by the Department of Health and Human Services to provide coverage for the 
newly tested conditions. 
56
 This signifies a remarkable victory for parents, because the new 
diseases added by the federal panel will be paid for through insurance because of the 
implementation of the ACA. 
The Advisory Committee on Heritable Disorders in Newborns and Children also has the 
authority to review diseases, disorders and conditions that individuals seek to include on the 
Recommended Newborn Screening Panel (RNSP).
57
  The RNSP is a comprehensive list 
approved and recommended by the Secretary of DHS for states to screen as part of their 
individual state newborn screening programs.
58
  In order to include a condition on the RNSP, 
individuals and organizations must partake in an application process wherein they nominate the 
condition they desire to by included on the panel.
59
  The application includes multiple letters in 
support of the condition being added, supporting data and scientific/clinical references to support 
its inclusion.
60
  In addition, conflict of interest disclosures on behalf of the individuals and 
organizations must also be submitted.
61
  Once the application is complete, it is then reviewed by 
the Advisory Committee’s Nomination and Prioritization Workgroup who compiles a summary 
                                                        
55
 See id.  
56
 See Genetic Alliance Applauds Supreme Court Decision on Affordable Care Act, 
http://www.geneticalliance.org/genetic-alliance-applauds-supreme-court-decision-affordable-care-act, (Last visited 
Dec. 8, 2013). 
57
 See Discretionary Advisory Committee on Heritable Disorders in Newborns and Children, Nominate a Condition, 
http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/nominatecondition/index.html, (last 
visited Dec. 8, 2013) 
58
 See id. 
59
 See id. 
60 See id. 
61
 See id. 
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of the information submitted that is then provided to the Secretary of DHS who makes the final 
decision as to the disease’s inclusion on the RNSP.62 
 
VI. NEWBORN SCREENING IN NEW JERSEY AND NEW JERSEY 
 
 As stated above, currently, the federal government recommends diseases, disorders and 
conditions to be screened through state Newborn Screening programs.  As such, each state 
adopts its own newborn screening laws, develops its policies and procedures related to the 
newborn screening and operates their own individual newborn screening.  Thus, the diseases, 
disorders and conditions screened for vary from state to state.   
 In New Jersey and New York, over forty diseases, conditions and disorders are screened 
for under their newborn screening laws.
63
  This section will compare the diseases screened for by 
the newborn screening panels in New Jersey and New York.   
 
A. Newborn Screening in New Jersey 
 
 Currently, New Jersey has expanded its statewide system of screening to include a total 
of fifty-four (54) disorders, diseases and conditions, both primary and secondary as defined by 
the RNSP, which, if not detected early, can lead to severe health problems and interfere with the 
                                                        
62
 See id. 
63
 See What is Newborn Screening, http://www.state.nj.us/health/fhs/nbs/faq.shtml (Last visited Dec. 8 2013); 
Wadsworth Center, New York State Department of Health http://www.wadsworth.org/newborn/ (Last visited Dec. 
8, 2013). 
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physical and mental development of the newborn.
64
  Together, these fifty-four diseases and 
disorders can be characterized into eleven disease groups for further clarification.   
The first group of disorders tested under the New Jersey law are Biotinidase Deficiency 
disorders. Biotinidase deficiency results from defective activity of an enzyme that links biotin to 
other essential substances in the body.
65
 A failure to diagnose and treat the deficiency causes 
permanent neurological damage and mental retardation in an infant. However, early diagnosis 
and treatment with pharmacological doses of biotin produce “marked improvement.” 66  In fact, 
pre-symptomatic treatment can result in the normal development of the infant.
67
  It will also 
enable the infant to lead a healthy life.  Testing for these deficiencies are also recommended by 
the Secretary of DHS.
68
  
 The second group of diseases are characterized as Congenital Adrenal Hyperplasia 
(CAH).  CAH is a family of disorders whose common feature is an enzymatic defect in the 
steroidogenic pathway leading to the biosynthesis of cortisol.
69
 The 21-hydroxylase enzyme 
deficiency accounts for 90-95% of CAH cases, resulting in ambiguous genitalia in females and 
salt-wasting crises in either males or females.
70
  When infants suffer from Congenital Adrenal 
Hyperplasia, their bodies cannot retain salt, which is often referred to as salt-wasting.
71
  
Treatment for this disorder consists of hormone medications, along with monitoring and lifelong 
                                                        
64
 See Disorders Screened in New Jersey, http://www.nj.gov/health/fhs/nbs/disorders.shtml, (Last visited Dec. 8, 
2013). 
65
 See Biontindase Deficiency, http://www.state.nj.us/health/fhs/nbs/biotinidase.shtml, (Last visited Dec. 8, 2013). 
66
 See Sanford J. Fox &Diony Young, International Protection Of Children's Right To Health: The Medical 
Screening Of Newborns, B.C. THIRD WORLD L. J.1, 9 (1991) (discussing biotindase deficiency). 
67
 See id. 
68
 See id. 
69
 See Congenital Adrenal Hyperplasia, http://www.state.nj.us/health/fhs/nbs/cah.shtml, (Last visited Dec. 8, 2013). 
70
 See id. 
71
 See id. 
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treatments.
72
 Detecting this disorder through newborn screening allows an infant to have a 
normal life without intellectual and physical disabilities.
73
  
 Another group of diseases that are tested for include Congenital Hypothyroidism.  Infants 
that are born with congenital hypothyroidism are unable to produce adequate amounts of the 
thyroid hormone called thyroxine.
74
  This hormone is integral for the normal function and 
development of all of the body’s organs and is essential for the normal development of the 
brain.
75
  Without treatment, this disorder leads to cognitive and intellectual developmental 
delays.
76
  It can also be acquired later on life.
77
 Treatment for Congenital Hypothyroidism 
includes thyroid hormone therapy.
78
 In addition, infants cannot be fed soy, fiber and iron.
79
 
 Under the New Jersey law, cystic fibrosis is another disease that is required to be tested.  
According to the NJ State Department of Health, it is the most common recessive genetic 
disorder in Caucasians in the U.S., Cystic Fibrosis occurs as a result of a defective Cystic 
Fibrosis Transmembrane regulator that results in thick mucus membranes, chronic obstructive 
lung disease and recurring pulmonary infections that can lead to death.
80
  Cystic Fibrosis can be 
treated through nutritional care, such as a high calorie diet.
81
  There is no known cure for cystic 
fibrosis and antibiotics and medical aggressive airway clearance techniques are often part of the 
treatment of this disease.
82
  
                                                        
72
 See id. 
73
 See id. 
74
 See Congenital Hypothyroidism, http://www.state.nj.us/health/fhs/nbs/congenital.shtml, (Last visited Dec. 8, 
2013). 
75
 See id. 
76
 See id. 
77
 See id. 
78
 See Liz Smith, Updated AAP Guidelines on Newborn Screening and Therapy for Congenital Hypothyroidism, 1 
AM FAM PHYSICIAN, 439, 441 (2007). 
79
 See id. 
80
 See Cystic Fibrosis, http://www.state.nj.us/health/fhs/nbs/fibrosis.shtml, (Last visited Dec. 8, 2013). 
81
 See id.. 
82
 See id. 
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 Fatty acid oxidation disorders are also tested under the Newborn Screen Program in New 
Jersey.
83
  Fatty acid oxidation disorders are inherited metabolic conditions that impair fatty acid 
metabolism.  Each fatty acid oxidation disorder is associated with a specific enzyme 
shortcoming.
84
  The most serious problem associated with fatty acids is that without them, the 
body can run out of energy and will often cease to function.
85
  Without treatment, fatty acids that 
cannot be broken down will result in damage to an infant’s heart and liver.86  Through proper 
diet, exercise and monitoring, fatty acid oxidation disorders can be controlled, although not 
cured. 
87
 
 Galactosemia disorders are another condition that is screened for under the New Jersey 
newborn screening program.  It is an autosomal recessive disorder of carbohydrate metabolism.
88
   
This deficiency results in the build up of galactose in the body, which causes physical symptoms 
and discomfort following lactose ingestion.  If an infant is found to have this condition, they are 
immediately placed on a soy diet and cannot be breastfed.
89
 If Galasctosemia disorders are 
untreated or not discovered, they can result in the death of the infant.
90
 
 Genetic disorders characterized as Sickle Cell Diseases are another group of disorders 
that are tested through the newborn screening program in New Jersey.  This disorder affects 
hemoglobin, which is the molecule in red blood cells used to deliver oxygen throughout the 
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body.
91
  These diseases are tested in newborns; however, the classic signs and symptoms do not 
develop until later on in life.
92
  In addition, bone marrow transplants often are the only cure for 
this disease.  However, treatment can be administered through prophylactic antibiotics and 
appropriate immunizations to prevent infection.
93
 
Another group of disorders screened for in New Jersey are Maple Syrup Urine Diseases.  
These are another autosomal recessive disorder.
94
  They are associated with progressive 
neurological damage that can lead to death.
95
  Treatment for these diseases must be continued 
throughout life and consist of a strict diet of amino acids.
96
  Through newborn screening, early 
detection of this disease is possible.  In fact, normal development and positive neurologic 
outcomes have been observed in infants who started treatment prior to developing this disease.
97
 
Organic Acidemia Disorders are another group of conditions tested under New Jersey’s 
newborn screening laws. Organic Acidemias disorders are inherited metabolic disorders that 
result in the accumulation of organic acids in blood and urine.
98
  Treatment options for this 
disorder include low protein diets, carnitine and vitamin supplements.
99
  Monitoring of the 
infants development is an important part of the treatment for those infants with Organic 
Acidemia Disorders.
100
 
The most famous disease tested is Phenylketonuria (PKU).  PKU was the first disorder to 
be tested through the administration of the newborn screening exam.  It is a rare genetic 
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condition in which an infant is unable to breakdown the amino acid phenylalanine in the blood, 
which results in mental retardation and developmental delays.
101
  This disorder is often inherited 
and occurs when the body cannot use the amino acid phenylalanine properly.
102
  Treatment for 
PKU must begin as early as possible. It consists of selectively restricting dietary phenylalanine 
except for the precise amount needed for the infant’s healthy growth and development.103  This is 
preformed by providing infants with a special formula and as they grow and develop, placing 
them on a diet that is low in phenylalanine but high in other essential nutrients.
104
  If treatment is 
successful, the infant will be able to have normal physical and mental development.
105
 
The last group of disorders are called Urea Cycle Disorders.  Urea cycle disorders are 
characterized by an accumulation of ammonia and its precursor amino acids that result in the 
defect in the urea cycle.
106
 Clinical symptoms for this disorder usually appear when the infant is 
one to three days old.
107
  When the disorder develops, the newborn undergoes rapid neurological 
deterioration.
108
   As the ammonia levels in the child’s body increases, the infant develops 
anorexia, hypothermia, irritability and seizures.
109
   Without intervention, infants often become 
comatose and die.
110
  Treatment for this disease includes providing the correct amount of protein 
in the infant’s diet so that they can grow and develop.111 
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 Most recently, New Jersey became one of the few states to include Krabbe 
Leukodystrophy to the New Jersey newborn screening panel.
112
 Krabbe disease is an autosomal 
recessive lysosmal storage disorder that affects the central nervous system. 
113
 The significance 
of testing for Krabbe disease in New Jersey represents a huge step towards newborn screening of 
neurological disorders. 
In early 2013, New Jersey became only the fifth state to add Krabbe’s Disease to their 
state newborn screening panel.
114
  This represented a huge victory for advocates of this deadly 
neurological disorder as well as the infants born with this disorder.  Similar to the other diseases 
screened for in New Jersey, Krabbe Disease is an autosomal recessive disorder that is associated 
with mutations in the galactosylcermidase gene (GALC). 
115
 When the GALC gene is mutated, it 
produces toxic substances in the brain, causing myelin loss, changes in the brain cells, and severe 
neurological damage.
116
 
 Unlike some of the diseases tested by newborn screening panels, Krabbe Disease has 
variable ages of onset and forms of progression.  It is characterized into four types- early 
infantile, late infantile, juvenile and adult.
117
  Children with early-infantile Krabbe disease show 
symptoms of developmental delays before six months of age.
118
  It typically leads to death before 
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the age of two.
119
  Late-infantile Krabbe disease is also deadly and has an onset between six and 
three months of age.
120
  Children with juvenile Krabbe disease become symptomatic between 
three and eight years of age and may have a longer survival time. 
121
 Adult-onset Krabbe disease 
is even more inconstant.  Affected individuals may have a normal life span.
122
  
 The addition of Krabbe disease to the newborn screening panel in New Jersey signifies a 
change in the philosophy that newborns should only be screened for treatable or preventable 
conditions.  Presently, there is no known cure for Krabbe’s Disease.  For those infants and 
individuals who acquire this disease, treatment is limited to supportive care, palliative care and 
drug therapy to control irritability.
123
  Currently, the only temporary curable treatments available 
are the transplantation of umbilical cord blood, hematopoietic stem cell transplantation and 
allogeneic bone marrow transplantation.
124
  These treatments have resulted in less severe signs 
and symptoms and significant delays in the onset of symptoms.
125
 
  In general, newborn screening in New Jersey is paid for through insurance.
126
  
 In addition, initial newborn screening collection forms are purchased by hospitals at a cost of 
ninety dollars per form.
127
  This cost is incorporated into labor and delivery charge.
128
   
 
B. New York’s Newborn Screening Law 
                                                        
119
 See id. 
120
 See id. 
121
 See id. 
122
 See id. 
123
 See id. 
124
 See Krabbe Disease, http://ghr.nlm.nih.gov/condition/krabbe-disease, (Last visited Dec. 8, 2013). 
125
 See id. 
126
 See Conditions Screened by State, http://www.babysfirsttest.org/newborn-screening/states/new-jersey, (Dec. 8, 
2013). 
127
 See id. 
128
 See id. 
 21 
 Similar to the diseases screened by the Newborn Screening Panels in New Jersey, New 
York also screens for many of the same diseases, conditions and disorders.  Such groups of 
diseases and disorders include Endocrine Disorders, which include Congenital Adrenal 
Hyperplasia and Congenital Hypothyroidism, various Hempglobinopathies such as Sickle Cell 
disease, Amino Acid disorders such as PKU, Fatty Acid Oxidation Disorders, Organic Acid 
Disorders and Urea Cycle Disorders.
129
  In addition, like New Jersey, New York screens for 
Biotindase Deficiency, Cystic Fibrosis, and Galactosemia.
130
  
 Unlike New Jersey, the major difference between the diseases screened by both states 
newborn screening panels is that New York requires the mandatory screening of the Human 
Immunodeficiency Virus (HIV).  Newborn screening tests in New York examine the infant’s 
blood for the presence of HIV antibodies.
131
   If HIV antibodies are detected in the infant, the 
mother is also infected with the virus.
132
  Under the newborn screening laws in New Jersey, HIV 
testing is not mandatory.  However, since 1995, regulations in New Jersey have required all 
pregnant women to be offered HIV counseling and voluntary HIV tests.
133
  
 New York was the first state in the country to include Krabbe Disease to its screening 
program in August 2006.
134
 The impetus for the inclusion of this test by the New York newborn 
screening panel came from the advocacy group, Hunter’s Hope who is currently trying to lobby 
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all states for the inclusion of this disease in their newborn screening programs.
135
  They argued 
that Krabbe disease should be added to New York’s newborn screening panel because of the 
possibility of preventing the disease’s development through chord blood transplants. 136   
Newborn screening for Krabbe disease could allow doctors to pre-symptomatically identify if an 
infant is susceptible to develop the disease, and treat it.
137
  Soon after New York began testing 
for this disease, other states, such as New Jersey followed.  
 
VII. INCLUSION OF ALZHEIMER’S DISEASE TO NEWBORN SCREENING PANELS 
 
 There is a valid argument for including Early-onset Alzheimer’s disease on the list of 
diseases tested on newborn screening panels in New Jersey, New York and most importantly on 
Federally recommended list.  Through scientific advancements and technology, it is easy to 
predict if one is a carrier of this degenerative, neurological disorder.  In addition, since this type 
of Alzheimer’s is the most rare form, individuals susceptible to this disorder should have the 
right to know that they may acquire it. 
 Furthermore, unlike Krabbe’s disease, which is already included in some newborn 
screening panels, a neurological disorder for which there is no cure, science has demonstrated 
that through intervention and therapy, the risk of developing Early-onset Alzheimer’s disease 
may be reduced by living a particular type of lifestyle
138
.  This is something that can be taught to 
children who have an increased risk of developing this disease.  Therefore, if states such as New 
Jersey and New York are at the forefront in beginning to screen newborns for neurological 
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disorders that are deadly, they should consider screening for neurological disorders whose onsets 
can be delayed.  
 
A. Overview of Early- Alzheimer’s Disease   
 
 Alzheimer’s disease is a degenerative disease of the brain that results in dementia.139  
According to the National Institute of Dementia and Stroke, dementia occurs when brain cells 
die.
140
  Brain cell death is not an immediate occurrence.
141
  Rather, it is progressive and occurs 
over time.
142
  Symptoms of dementia include the gradual loss of memory, judgment and the 
ability to process information so that an individual may function.
143
 
 There are two types of Alzheimer’s disease: early onset or familial and late-onset.  Early 
on-set Alzheimer’s disease occurs in those individuals who acquire the disease at age sixty-five 
(65) or under.
144
 This article solely focuses on the genetic testing of children for Early-onset 
Alzheimer’s disease as it is the type of Alzheimer’s that is the rarest and most easily detected 
through genetic testing.   
The genetic origin of Early-onset Alzheimer’s disease is easily understood.  Most cases 
of Early-onset Alzheimer disease are caused by gene mutations that can be passed from parent to 
child.
145
 The Early-onset familial form of the disease can arise in individuals who are in their 
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forties and fifties, and in very rare cases can develop in people who are thirty years of age.
146
 
However, it is generally characterized as occurring in individuals age sixty-five (65) and 
under.
147
  With this familial form of Early-onset Alzheimer's, there usually will be many parents, 
siblings and cousins who acquire the disease and also have dementia.
148
 When an individual is a 
carrier of one of the gene mutations that cause Early-onset Alzheimer’s disease to develop, it is a 
good predictor that they are susceptible to develop this debilitating disease.
149
 
 As the progression of the disease worsens, people with Early-onset Alzheimer’s disease 
experience personality and behavioral changes that make social integrations difficult for them.
150
  
As a result, individuals suffering from this disease experience frequent agitation, restlessness, 
withdrawal and even the loss of language skills.
151
    
 The genes associated with Alzheimer’s disease are amyloid precursor protein (APP), 
Presenilin (PSEN-1 and PSEN-2) and appolipoprotient (APOE).
152
   Mutations in APP result in 
an incorrect amount of the protein, which produces a version of amyloid β that is more likely to 
form plaques. Mutations in APP account for ten to fifteen percent of familial Early-onset 
Alzheimer's disease cases.
153
  The PSEN genes encode proteins that function in the cleavage of 
Amyloid Precursor Protein.
154
 Mutations in both PSEN1 and PSEN2 result in incorrect cleavage 
of APP, and are associated with the development of familial Early-onset Alzheimer’s disease.155  
Mutations in PSEN1 are thought to account for 30%-70% of familial Early-onset Alzheimer 
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disease developments, while mutations in PSEN2 are thought to account for less than 5%.
156
 
Children of an affected parent have a 50% chance of inheriting the mutation and 
developing Early-onset Alzheimer’s Disease. It is important to note that mutations in APP, 
PSEN1 and PSEN2 do not account for all of the genes that result in familial early-onset 
Alzheimer’s disease.157  In fact, scientists believe that there are other genes that attribute to this 
disease that are not known at this time and likely to be discovered in the future.
158
   However, 
mutations in these genes will likely lead to the development of Early-onset Alzheimer’s disease. 
 
B. Therapy, Prevention and Intervention 
 
In addition to genetics in predicting the possibility of acquiring Early-onset Alzheimer’s 
Disease, environmental factors, lifestyle choices, among many other factors can also attribute to 
the development of the disease.
159
  Thus, with this known, it is important to know whether an 
infant is a carrier of the genes in order to delay the progression and onset of the Early-onset 
Alzheimer’s disease occurring later on in life.  Therefore, the testing for the genes associated 
with Early-onset Alzheimer’s disease is important to include in newborn screening programs so 
that the onset of the disease is delayed and individuals can have a longer and healthier quality of 
life. 
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Over the last three decades, researchers have found that parents who warn their children 
about the risk of developing Alzheimer’s Disease has lead to its delayed development. 160  
Knowledge is power.  Knowing this from a very young age, leads to, what scientists refers to as 
“building your cognitive reserve.”  According to this theory, by exercising and developing the 
mind as early as possible, later on in life, when Early-onset Alzheimer’s Disease begins to 
deteriorate the brain, people with the largest and most comprehensive cognitive reserves would 
experience less brain deterioration.
161
   Cognitive reserve has also been used to explain the 
neuropatholgic changes associated with coping with Alzheimer’s disease.162  According to the 
American Academy of Neurology, cognitive reserve capacity is set early on in life and gradually 
changes as the nervous system changes.
163
  As individuals age, those with a higher reserve 
capacity will have a lower risk of developing dementia.
164
 This is significant, because, since 
Early-onset Alzheimer’s disease is very predicable through genetic testing, families should have 
the right to know that their children are carriers of genes so that they can start cognitive therapy 
early on in life. 
Another treatment recommended for the prevention of Alzheimer’s is physical, 
cardiovascular exercise.
165
    The scientific and medical communities have established that 
evidence suggests that cholesterol plays a role in the development of Alzheimer disease in 
general.
166
 Therefore, individuals who build in regular cardiovascular exercise into their daily 
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routine are less likely to develop Early-onset Alzheimer’s disease.167  In fact, individuals who 
exercised regularly have about half the risk of developing dementia then those who do not 
exercise. Therefore, it is important for children to be brought up knowing the importance of 
exercising and engaging in actual exercise so that those, who are carriers of the genes associated 
with Early-onset Alzheimer’s disease, can reduce their risk of acquiring the disease later on in 
life.
168
 
Finally, a change in diet may reduce the risk of developing Early-onset Alzheimer’s 
Disease.
169
  According to the Physician’s Committee for Responsible Medicine, there are seven 
dietary principles that are proven to reduce the risk of Alzheimer’s disease.170 These principles 
were revealed during the International Conference on Nutrition and the Brain.
171
  They include 
reducing your intake of saturated and trans fats and cooperating vegetables, fruits and whole 
grains into your diet.
172
  Those individuals who are susceptible to developing Early-onset 
Alzheimer’s disease should incorporate Vitamin E and B12 into their daily vitamins.   When 
selecting multiple vitamins, those at risk for Early-onset Alzheimer’s disease should avoid iron 
and copper.
173
 Providing this information to parents enables them to educate their children and, 
through physician supervision, integrate these vitamins into their children’s daily diet. 
 
C. Ethical Considerations and Policy Recommendations 
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While the technology is available for Early-onset Alzheimer’s disease to be screened in 
newborns, there are still several ethical questions that arise, especially since even the earliest 
indications of this disease occur once a child has matured into an adult.  In particular, it is 
important for parents to proceed with caution in acquiring this information and utilizing it in 
their child’s daily life. 
The genetic testing for Early-onset Alzheimer’s disease in newborns can present some 
ethical problems in regard to the child’s autonomy.  This discussion ultimately focuses on whose 
right to autonomy is jeopardized; the parents or the childs, when there is no immediate identified 
medical benefit.  If parents chose to have their child tested to their susceptibility for obtaining 
Early-onset Alzheimer’s disease, the child’s right to autonomy is violated.   However, with the 
technology available to predict this disease in infants, there is an argument to be made that 
denying this test to parents deprives their children of health care that could provide them with a 
better quality of life.   
In addition, the physiological effects of telling a child that they are susceptible to 
developing Early-onset Alzheimer’s disease still needs to be determined.  Children are 
vulnerable and basically telling a child that they will one day lose their ability to remember 
memories and information can have detrimental effects on the child’s development. The 
scientific and medical communities are yet to determine the implications that result from when a 
child learns this information.  In addition, their still needs to be more information available as to 
what the appropriate age is a that a child should learn that they are likely to develop Early-onset 
Alzheimer’s disease in the future.     
Furthermore, if infants and children are treated for their susceptibility in developing 
Early-onset Alzheimer’s disease, there needs to be strict physician guidance in overseeing these 
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treatments.   Also, guidelines need to be implemented as to what types of treatments can be used 
in children and the safety of these treatments.  This guidance should be established on the federal 
level so that a least, minimum standards are developed through state implementation.   
Infants with negative or unclear newborn screening test results also need have the 
newborn screening test re-administered to them.  This re-administration should be performed at 
no additional cost to parents.  Rather, should either be paid for through insurance or by the state. 
As to the unification of newborn screening panels nationwide, there needs to be an 
incentive for states to adopt all the diseases recommended by the Uniform Screening Panel.  By 
doing so, this will ensure that all newborns are screened for diseases that can save their lives.  
This should not be viewed as a mandate or a political agenda.  Rather, it should be considered a 
public health initiative.   The Secretary of DHS should evaluate the current list of diseases 
screened, together with all the other diseases that states screen for to make “master” list of 
diseases that should be screened.  This process would appear to be faster then the current process 
of medical professionals and individuals submitting an application to the Department for review.  
Together, it is important that these ethical considerations and policy recommendations are 
considered when adding Early-onset Alzheimer’s disease to newborn screening panels. 
 
D. Application of the Wilson and Jungner Test Supports Adding Early-onset  
Alzheimer’s Disease to Newborn Screening Panels 
 
 
In addition to these treatments proven to delay the onset of Early-onset Alzheimer’s 
disease, it also passes the Wilson and Jungner classic screening criteria for inclusion on newborn 
screening panels discussed is Part I, Section A. 
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According to Wilson and Jungner, there are five criteria that must be met for a genetic 
disorder to be screened.
174
  According to them, in order for a disease to be screened, it must be 
well defined and serious.
175
  Early-onset Alzheimer’s disease is a defined neurological disorder 
that results in clinical symptoms resulting in the progression of cognitive and behavioral 
impairment.
176
 Therefore, the disease is defined as serious as required under the Wilson and 
Jungner criteria.  
Second, Wilson and Jungner state that there must be an accurate testing method available 
for the genetic disease.
177
 The Newborn Screening Quality Assurance Program (NSQAP) is a 
voluntary, non-regulatory program established by the federal government to aid state health 
departments and their laboratories in maintaining accurate newborn screening test results.
178
  The 
NSQAP provides proficiency-testing services, which give state laboratories, coded specimens of 
the diseases screened to help scientists and doctors determine the results of the administered 
newborn screening test.
179
  Therefore, there is accurate testing available for Early-onset 
Alzheimer’s disease.  
Third, the costs of the test must be reasonable. According to the New Jersey State 
Department of Health, the cost of newborn screening is covered through insurance so it is 
reasonable.
180
  In New York, the cost of newborn screening is absorbed by the state.  Therefore, 
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the cost of newborn screening to detect Early-onset Alzheimer’s disease is reasonable as there 
are already numerous diseases that states and insurance companies pay for that are tested.   
The forth criteria established by Wilson and Jungner is that there must be available 
treatment for the disorder.
181
   Recent medical studies have indicated that there is treatment 
available to help delay the onset of Alzheimer’s disease in general. 182   Such therapies and 
treatments include exercising and developing the mind as early as possible.  Therefore, it this 
criterion is also satisfied. 
The last Wilson and Jungner criterion is that there must be adequate medical management 
facilities to refer infants for confirmatory diagnosis and treatment.
183
  This is satisfied though the 
sophistication of hospitals and medical facilities.  In addition, health care systems across the 
county are developing specific treatment centers for Alzheimer’s diseases treatment.  Most 
recently, Capitol Health’s Institute for Neuroscience announced that it will be opening a 
specialized program focusing on the treatment of Alzheimer’s disease in New Jersey.184 
Based upon the above analysis, it is evident that Early-onset Alzheimer’s disease passes 
renowned criteria set forth by Wilson and Jungner needed for diseases to be included in newborn 
screening panels.  If we were to apply this same test to Krabbe’s disease, in which there is no 
cost-effective treatment for and no known cure, it appears that it would not pass the Wilson and 
Judger test.  Despite this, New Jersey and New York have already added this disorder to their 
state newborn screening panel.  Therefore, this provides a strong argument for the inclusion of 
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Early-onset Alzheimer’s disease to newborn screening panels at least on the federal Uniform 
Newborn Screening Panel.  
 
V. CONCLUSION 
 
This paper discussed the importance of states adopting all of the diseases recommended 
by the RNSP to their individual newborn screening programs.  If this is not accomplishment, 
there is a possibly that some infants will die as a result of their state not choosing to screen for a 
particular disease recommended by the RNSP.  Evidence of this has already occurred from some 
states not choosing to screen for Krabbe disease as discussed above.  It the testing and treatment 
is available to save the lives of infants, not utilizing it is a foolish. 
In addition, this paper also discussed the importance of including Early-onset 
Alzheimer’s disease to the list of federally recommended screened diseases, conditions and 
disorders approved by the Secretary of DHS.  Based upon the information known about Early-
onset Alzheimer’s disease and the medical research available that confirms possible treatments 
and interventions for the disease, it is clear that this disease should be added to the federal list of 
diseases that are recommended to be screened for in newborns. In addition, addition Early-onset 
Alzheimer’s disease passes the criteria for screening diseases established by Wilson and Jungner.  
As evidenced in this paper, Krabbe disease, which is already screened for by some states does 
not pass this well-established criteria.  It is important to note that there are treatments and 
interventions available to delay the onset of Early-onset Alzheimer’s disease. Therefore, this 
presents a strong argument that favors adding Early-onset Alzheimer’s disease to the federal 
panel.   
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Furthermore, with the ACA requirement that all diseases recommended by the federal 
panel be paid for through insurance, more infant lives will be saved, regardless of whether or not 
their state screens for the disease.  This is a significant advancement in newborn screening and 
demonstrates the importance of screening infants for all the diseases federally recommended. 
Therefore, Early-onset Alzheimer’s disease should be added to the Recommended Newborn 
Screening Panel.  If this cannot be accomplished, Early-onset Alzheimer’s should be included as 
a disease tested in New York and New Jersey’s newborn screening panels.   
With the ability to test if an infant is a carrier of the genes associated with Early-onset 
Alzheimer’s disease, medical research suggests that through therapies and interventions, its onset 
can be delayed.  Therefore, the testing for these genes is important so that those individuals who 
are susceptible for acquiring Early-onset Alzheimer’s disease can have a healthier and better 
quality of life and slow the progression of this devastating illness. 
